Efficacy of Sodium-glucose Cotransport-2 Inhibitors of fixed dose in Heart Failure Patients: A Network Meta-analysis
Abstract
Review question / Objective: To compare the efficacy of SGLT-2i on prognostic improvement of heart failure.Condition being studied: The prognostic improvement of dapagliflozin and empagliflozin in Sodium-glucose Cotransport-2 Inhibitors (SGLT-2i) in patients with HF has been discovered.However which drug could improve varied prognostic outcomes have not been elucidated.Eligibility criteria: Inclusion criteria: (1) study subjects were patients with HF; (2) the drugs applied were dapagliflozin, empagliflozin, and placebo; (3) drug doses were consistent with most studies (both were10mg per day); (3) RCTs; and (4) reported at least one prognosis endpoint of interest.INPLASY registration number: This protocol was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY) on 10 January 2022 and was last updated on 10 January 2022 (registration number INPLASY202210046).
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.